VIP Peptide for CIRS: The Vasoactive Intestinal Peptide Protocol
Vasoactive intestinal peptide (VIP) is a neuropeptide used in the final phase of CIRS treatment. Learn dosing, eligibility criteria, lab markers, and clinical evidence.
Infectiology
Emerging EvidenceMold & CIRS
Chronic inflammatory response syndrome from biotoxin and mold exposure.
01
02
CIRS Treatment Protocol: The Shoemaker Steps and Integrative Additions
A physician's roadmap to treating Chronic Inflammatory Response Syndrome—from CSM binding to VIP nasal spray—with integrative additions for refractory cases.
03
Mold Testing: Urine Mycotoxins vs ERMI vs Air Testing
Comparing mold testing methods — urine mycotoxin testing for body burden, ERMI for environmental exposure, and air sampling limitations. Which test you actually need.
04
CIRS vs MCAS: Overlapping Conditions Differentiated
How to distinguish CIRS from MCAS, why they frequently co-occur, and why treating only one often fails. HLA-DR genetics, mast cell activation, and the upstream driver.
05
CIRS Symptom Checklist: HLA-DR Genetics and Biotoxin Illness
The 37 symptoms of CIRS across 13 clusters, HLA-DR genetic susceptibility, and why 25% of the population cannot clear biotoxins normally.
06
Mold Illness and CIRS
Chronic Inflammatory Response Syndrome from mold exposure. How it overlaps with chronic infections, diagnosis, and treatment approaches.
